Table 3.

Summary estimates for ovarian/fallopian tube cancer and breast cancer risk reduction associated with salpingo-oophorectomy in BRCA1/2 mutation carriers^*

Summary characteristic	Ovarian and/or fallopian tube cancer by mutation status			Breast cancer by mutation status
	BRCA1/2	BRCA1	BRCA2	BRCA1/2	BRCA1	BRCA2
Studies included	(11,16,17)	NA	NA	(14–16)	(12,14–16)	(14–16)
HR (95% CI)	0.21 (0.12 to 0.39)	NA	NA	0.49 (0.37 to 0.65)	0.47 (0.35 to 0.64)	0.47 (0.26 to 0.84)
P value for heterogeneity among studies†	.999	NA	NA	.998	1.000	.604
P value for publication bias‡	.999	NA	NA	.602	.176	.602

^*NA = not applicable; HR = hazard ratio; CI = confidence interval.

^†Derived from χ² test.

^‡According to Begg and Mazumder (20).